logowsbdaily | Tue, 25 Jan 2022 08:54:46 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Revive Therapeutics Ltd.
(RVVTF)

Revive Therapeutics Ltd.
The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1
Canada
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the tre... Read More

Summary & Charts

Price$ 0.22-0.02 (-8.34%)
Day's Range$ 0.22 - 0.25 
Previous Close$ 0.24
Market Cap$ 70.12M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeOther OTC
IndustryDrug Manufacturers—Specialty & Generic
SectorHealthcare
Volume1.06M
Avg. Volume (20 day)606.66K
Rel. Volume (20 day)0.71
Rel. Volume (3 month)0.73
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Jan 18, 2022$ 0.24$ 0.25$ 0.22$ 0.22-0.02543,4830.710.73
Jan 14, 2022$ 0.27$ 0.27$ 0.24$ 0.24-0.01392,4000.510.53
Jan 13, 2022$ 0.26$ 0.26$ 0.23$ 0.25+0.00155,3000.200.21
Jan 12, 2022$ 0.25$ 0.27$ 0.23$ 0.25-0.00178,7000.230.24
Jan 11, 2022$ 0.22$ 0.25$ 0.22$ 0.25+0.00592,3000.690.80
Jan 10, 2022$ 0.25$ 0.27$ 0.23$ 0.24484,8000.560.66
Jan 07, 2022$ 0.22$ 0.27$ 0.22$ 0.24+0.011,351,5001.551.81
Jan 06, 2022$ 0.25$ 0.27$ 0.23$ 0.23-0.031,396,1001.721.92
Jan 05, 2022$ 0.28$ 0.28$ 0.26$ 0.27+0.00381,2000.500.542
Jan 04, 2022$ 0.29$ 0.29$ 0.26$ 0.26-0.02489,1000.650.70
Jan 03, 2022$ 0.25$ 0.29$ 0.25$ 0.29+0.02410,2000.540.58
Dec 31, 2021$ 0.27$ 0.27$ 0.25$ 0.27-0.002,402,4003.103.38
Dec 30, 2021$ 0.30$ 0.31$ 0.25$ 0.27-0.043,203,1004.644.66
Dec 29, 2021$ 0.30$ 0.34$ 0.29$ 0.31-0.021,062,1001.931.631
Dec 28, 2021$ 0.31$ 0.33$ 0.30$ 0.33+0.02568,5001.000.881
Dec 27, 2021$ 0.33$ 0.35$ 0.31$ 0.31-0.01338,6000.590.52
Dec 23, 2021$ 0.31$ 0.34$ 0.31$ 0.33-0.00347,7000.590.532
Dec 22, 2021$ 0.35$ 0.35$ 0.32$ 0.33483,7000.810.74
Dec 21, 2021$ 0.32$ 0.33$ 0.31$ 0.33+0.01244,9000.420.37
Dec 20, 2021$ 0.32$ 0.34$ 0.31$ 0.32-0.00297,9000.500.45

News

The latest news about Revive Therapeutics Ltd. (RVVTF).

Proactive Investors | 2022-01-07 08:07:41
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) told investors it expects to complete patient enrollment of its Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19) in the first quarter of 2022. In a statement clarifying the status of the trial, the life sciences company noted that as of  December 29 last year, there had been around 700 subjects who had "participated in the enrollment period" of the study.
Proactive Investors | 2021-12-30 09:22:44
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that its U.S. Food and Drug Administration (FDA) Phase 3 clinical trial study evaluating the safety and efficacy of Bucillamine— an oral drug with anti-inflammatory and antiviral properties — in patients with mild to moderate coronavirus (COVID-19) has screened approximately 700 subjects to date.  The company said that it has decided to fill a part of its patient enrollment quota outside of the U.S.
Proactive Investors | 2021-12-03 09:34:42
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has decided to expand research with Bucillamine as a potential treatment for the coronavirus Omicron variant.  It is an oral drug shown to have promising anti-viral and anti-inflammatory capabilities and is being evaluated in a current Phase 3 clinical study for coronavirus (COVID-19).
Proactive Investors | 2021-11-23 08:11:42
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) revealed that it has filed an application with the US Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver transplantation. The Toronto-based life sciences company said that currently, there are no approved treatments available for IRI, a major complication of liver transplantation.
Proactive Investors | 2021-11-16 08:48:46
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced a research study showing that potent thiol drugs, such as Bucillamine, inhibit SARS-CoV-2 infection in vitro — especially the Delta variant. The drug also reduces SARS-CoV-2-related lung injury in vivo and provides a strong rationale for trials of systemically delivered thiol drugs as coronavirus (COVID-19) treatments.
GlobeNewsWire | 2021-11-16 06:00:00
TORONTO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled “Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro” from the University of California, San Francisco, showing that potent thiol drugs, like Bucillamine, inhibit SARS-CoV-2 infection in vitro, specifically the Delta variant (B.1.617.2), which is now globally dominant, and also reducing SARS-CoV-2-related lung injury in vivo and providing strong rationale for trials of systemically delivered thiol drugs as COVID-19 treatments. In addition to its anti-oxidant and anti-inflammatory properties that could limit lung injury in COVID-19, thiol drugs have promising antiviral effects.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2021-11-29AMC------------
2021-10-25AMC------------
2021-05-31BMO------------

Top Discussions

These are the top discussions over the last 24-hours that mention the RVVTF stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.